Background: In elderly hemodialysis patients, the risk of medication-related problems is particularly high.
Introduction
Issues associated with medication administration remain a major health care concern, particularly among elderly patients. A 2005 study in the United States found that adverse drug events (ADEs) occurred relatively frequently among ambulatory patients, with 27.6% found to be avoidable. [1] Hemodialysis patients are considered to be at higher risk for medication-related problems than the general population for several reasons, including impaired drug clearance, [2] increased frequency of polypharmacy, increased number of comorbidities, and increased proportion of receiving drugs that require therapeutic drug monitoring. [3] However, while previous studies have revealed that 98% of HD patients had at least one medication-related problem, [4] no efficient solutions have yet been proposed.
Identifying drugs carrying high risk of ADEs is one possible strategy for managing medication-related problems. In theory, reducing the likelihood of physicians prescribing such drugs consequently reduces the incidence of medication-related problems and ADEs. [5] These high-risk drugs are called "potentially inappropriate medication (PIM)" and are defined as "medication with no clear evidence-based indication, and which carry a substantially higher risk of adverse side-effects or are not cost-effective". [6] Several sets of criteria for PIMs have been developed specifically for use with elderly patients, with the Beers criteria the most commonly used in previous epidemiological studies. [6] Akazawa et al. reported that the frequency of prescribing PIM, as defined using a modified version of the Beers criteria reflecting regional clinical practice and available medications in Japan, was 43.6% among elderly patients in Japan. [7] However, this study population was made up of beneficiaries covered by the employees' health insurance system, which included healthier individuals than may be found in the general elderly population. As such, prescription patterns of Previous reports on the employees' health system have all involved relatively heterogeneous general elderly populations, failing to account for the fact that prescription patterns of PIMs may differ according to patients' comorbidities. A study surveying prescription patterns of these medications of elderly hemodialysis patients may therefore provide important information on the subject of the difference between healthy elderly patients and elderly patients with severe disease. Here, we attempted to determine the prevalence of and identify risk factors for prescribing PIMs in elderly hemodialysis patients.
Method

Study design and data source
We obtained all data from phases II (from year 2002 to 2004) and III (from year 2005 to 2008) of the Dialysis Outcome Practice Pattern Study in Japan (J-DOPPS II and J-DOPPS III), which were large cohort studies involving detailed data from adult HD patients at more than 50 randomly selected dialysis facilities in Japan.
DOPPS originally sought to determine dialysis practices which most contributed to improved mortality and hospitalization rates, health-related quality of life, and vascular access outcomes after adjusting for the effects of comorbid disease and other demographic confounding factors. The dialysis facilities included in DOPPS constitute a nationally representative sample. To ensure variation in practice patterns and outcomes, a stratified random sample of hemodialysis facilities was selected. DOPPS's methodology has been detailed previously, [8, 9] and all institutional review boards approved its conduct in each facility, as required.
Prescribed drug information and patients' demographic data were surveyed at study enrollment. This study was cross-sectional in design to examine the association between PIM and other factors.
Study population
To ensure a representative national sample, two-staged random sampling method was used in the J-DOPPS.
After first randomly selecting our 50 hemodialysis facilities of focus, we then randomly selected patients at those facilities in each study phase. Inclusion criteria for the present study were an age of 65 years or older and currently receiving chronic hemodialysis treatment. Patients receiving transient dialysis were excluded.
Outcome measurement
We used the modified Beers criteria for elderly Japanese populations to define PIMs, [7] identifying a total of 47 PIMs as selected by 9 expert panel members. The criteria consisted of either medications that should be always avoided or those which should be avoided only in particular situations. Participants receiving drug prescription classified as PIM only if prescribed long-term were additionally examined at one year after enrollment. Given that non-critical comorbidities such as insomnia were not recorded correctly in these studies, we defined insomniac patients as those who prescribed hypnotic agents and constipated patients as those who prescribed laxative agents. Medications that were to be avoided in patients with incontinence or urinary retention were excluded, as most hemodialysis patients are generally accepted to be anuric.
The primary outcome was prescribed at least one PIM as defined by the modified Beers criteria. Prevalence of PIM prescription was estimated. To evaluate changes over time in PIM prescription, we also compared the frequency of PIM prescription between J-DOPPS II and J-DOPPS III.
Statistical analysis
Differences in distributions of primary outcome within categorical valuables were compared using the χ 2 test.
Multiple logistic regression analysis was performed to determine patient characteristics associated with PIMs; the model included age, sex, vintage, number of co-morbidities, number of medications, dependency in activities in daily living (ADL; defined by using a wheelchair or similar aids), past history of depression, and living alone. Numbers of comorbidities and numbers of medications were divided into four groups based on variable quartile.
Given that facility characteristics were measured only in the J-DOPPS III cohort, we conducted sub-group analysis using only patients participating in J-DOPPS III to determine facility characteristic associated with prescription of PIMs. In this sub-group analysis, logistic regression analysis including the above patient characteristics and facility characteristics was performed. Number of hemodialysis stations was divided into dichotomous variables based on the median value. To estimate cluster effects of each facilities, two-stage random effect logistic regression analysis was also performed as sensitivity analysis.
Differences or associations with a two-sided P value of less than 0.05 were considered statistically significant. All analyses were performed using STATA version 11.2 (StataCorp LP, College Station, TX, USA).
Results
A total of 1367 elderly patients were deemed eligible for this study (Figure 1 ), and their characteristics are shown in Table 1 . Characteristics of patients were strikingly similar across both phases of J-DOPPS. Median age was 72 (range: 65-98) years, and 33% of patients were found to have diabetes as the primary cause of end-stage renal disease. Only 1% of patients had a history of definite diagnosis of depression. Details of facility characteristics in the J-DOPPS III cohort are available in the online appendix. Teaching hospitals made up 26% of facilities examined, and almost half of all facilities conducted multidisciplinary rounds (57%).
At least two physicians decided on dialysis treatment in 67% of all facilities. Figure 2 shows the distribution of the number of PIMs prescribed, revealing that most patients were prescribed one or two PIMs (52%). Table 2 shows the frequency of prescription of PIM and detailed lists of medications among this population. More than half of patients were prescribed PIM-most often H2 blockers.
A total of 38% of patients were prescribed famotidine at or exceeding 20 mg daily, the usual dose for patients with normal kidney function. The second most frequently prescribed PIM was cardiovascular drugs (Table 2) , primarily anti-platelet drugs such as ticlopidine (19%) and alpha-blockers (13%). As with patient characteristics, no remarkable differences in details of PIM were noted between the two J-DOPPS phases. analysis with two-staged random effect model showed no significant clustering at the facility level.
Discussion
The overall frequency of PIMs was 57% among Japanese elderly hemodialysis patients, a finding similar between both J-DOPPS phases examined. The most frequently prescribed PIMs in our study were H2 blockers, anti-platelet agents, and alpha-blocker agents. We noted no remarkable differences in details of PIM between the two different phases of J-DOPPS. Patients on hemodialysis for a relatively long time, prescribed many medications, or treated by more than one physician were at greater risk of PIM prescription than those not meeting these criteria. In contrast, patients treated at teaching hospitals or hospitals conducting multidisciplinary rounds were at relatively low risk of PIM prescription. Taken together, these findings suggest that elderly hemodialysis patients were prescribed PIM more frequently than previously reported for the general elderly population. [7] A previous study reported that 2.7% of general elderly patients were prescribed anti-platelet agents classified to a PIM, [7] compared with a proportion of 15% among elderly hemodialysis patients in the present study. Elderly hemodialysis patients were prescribed anti-platelet agents more often than non-hemodialysis patients given the increased incidence of vascular disease among elderly patients on hemodialysis. However, a previous study on antiplatelet therapy in vascular disease (ischemic stroke, coronary artery disease, and peripheral arterial disease) suggested that aspirin or clopidogrel should be used as first-line agents for the majority of the patients, as ticlopidine usage is limited by its life-threatening hematological adverse reactions including neutropenia, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia. Although clopidogrel, a possible alternative to ticlopidine, was not available in Japan at study enrollment for either cohort, we considered that ticlopidine should be prescribed more carefully.
Frequent use of H2 blockers was deemed one of the reasons for the high frequency of prescription of PIMs in the present study. Previous report from worldwide DOPPS reveals that proton pump inhibitors (PPI) were used much less often than H2 blockers in Japan (0.8% vs. 31.6%, respectively) and the frequency of prescription is very low compared to other country (14.0% to 27.3%) [10] . In Japan, the usual prescription of PPIs for gastric and duodenal ulcers is limited to 8 weeks. This limitation may affect the relatively high frequency of prescription of H2 blockers. H2 blockers are associated with mental status changes such as delirium and decline in cognitive function in elderly patients; [11] indeed, a previous study revealed that approximately 10% of adult end-stage renal disease patients with prescription of famotidine had shown mental status changes during over 7 years of follow-up. [12] While dose adjustment may decrease the frequency of ADE, 38% of patients were prescribed the usual dose of famotidine in the present study (20-40 mg daily).
While Akazawa et al. reported that 2.8% of general elderly patients were prescribed alpha-blockers classified to a PIM, [7] 12% of elderly hemodialysis patients were prescribed these drugs in our study. Report from DOPPS reveals that vasodilators are less often prescribed for hemodialysis patients in Japan than other countries. [13] Another previous study reported that alpha-blockers approximately tripled the risk of falling, [14] and a previous observational study showed that hemodialysis patients with alpha-blocker prescriptions had slightly higher mortality independent of variables such as age, sex, race, years of end-stage renal disease, or prevalence of co-morbidities. [13] Other anti-hypertensive drugs such as angiotensin converting enzyme (ACE) inhibitors, [15] angiotensin receptor blockers (ARBs), and beta blockers, [13] which are all associated with reduced mortality risk in hemodialysis patients, should be prescribed instead of alpha-blockers.
Under the modified Beers criteria, the following analgesics are classified as PIMs: indomethacin, pentazocine, long-term use of full-dosage long half-life non-COX-selective NSAIDs, and general NSAIDs prescription in patients with gastric or duodenal ulcers. As such, analgesic drugs classified as PIMs were rarely prescribed in the present study.
Here, we identified several factors associated with prescription of PIM, with our findings for polypharmacy and dependency in ADL consistent with those of previous studies. [16] Our findings also suggested that longer vintage may be associated with time-dependent increase of cardiovascular or gastrointestinal complications; therefore, patients receiving hemodialysis for a relatively long period of time may have more chances to be prescribed PIMs than those with shorter vintage. In contrast, several variables (number of co-morbidities, age, sex, past history of depression, living alone) already known to be associated with prescription of PIMs [16] were not found to be statistically significantly associated in the present study. We believe that number of co-morbidities was not an important factor influencing PIMs in the present study because hemodialysis status involves serious comorbidities. Given that markedly few patients had a definite history of depression or were older than 85 years, we were unable to detect statistically significant differences in the frequency of PIMs among this population.
In multivariable analysis of the J-DOPPS III cohort, PIM prescription was found to be associated with several facility factors. Patients at teaching hospital may receive relatively high-quality treatment, thereby avoiding many medication-related problems. We further believe that multidisciplinary rounds were useful in facilitating sharing of information about ADEs between physicians and other health care providers, possibly resulting in avoiding prescription of PIM; this finding is consistent with previous studies, further underscoring the efficacy of a multidisciplinary team in avoiding PIM. [17] Having more than one dialysis physician make the decision to change hemodialysis regimen may increase the opportunity to be prescribed PIMs. Taken together, these findings suggest that prescription of PIM was affected by modifiable practice patterns.
Six major limitations to the present study warrant mention. First, because of the cross-sectional study design, causal inferences cannot be made. However, as mentioned above, variation in these facility factors (teaching hospital, multidisciplinary rounds conducted, or changing of the hemodialysis regimen by more than one physician) cannot logically be deemed to be due to prescription of PIM. We thought that these factors were the cause or preventive factors of PIM. Second, information regarding patient disease history was limited to 29 diseases, thereby reducing the frequency of PIMs to be taken into account in patients with certain disease such as hyponatremia. This limitation may have thereby led to underestimation of the frequencies of PIM. Third, as we used Beers criteria to identify PIMs, other medications that are at high risk for ADEs in hemodialysis patients may not be included. This limitation may also lead to underestimation of the frequencies of PIM. Fourth, some patients may have been redundantly selected for both the J-DOPPS II and J-DOPPS III through random sampling. However, we assume that the percentage of such patients is negligible.
Fifth, the present study used data from Japanese hemodialysis patients; as such, global application of our findings will require further investigation. Sixth, association between PIMs and clinical outcome was unclear in elderly hemodialysis patients. [18] Further study will be needed to clearly determine the clinical impact of PIMs in this patient population.
In conclusion, the fact that PIMs were prescribed to more than half of the patients in this study underscores the importance of medication management in elderly people receiving hemodialysis. Nephrologists should be aware of the frequency and dangers of prescribing PIMs. In addition, we realize that for all hemodialysis facilities to implement all of the practices that are common in teaching hospitals might be impractical. Further research should be done on the practices that are common in teaching hospitals, to find out which among them most strongly inhibit the prescription of PIMs. We believe that, as a minimum, multidisciplinary rounds
should be conducted at all facilities where they are possible. 
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